View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 21, 2022

Hinova doses first patient in Phase I castration-resistant prostate cancer trial

HP518 is highly selective for AR, a therapeutic target which has been validated for prostate cancer treatment.

Hinova Pharmaceuticals has dosed the first subject in a Phase I clinical trial of its oral therapy HP518 to treat metastatic castration-resistant prostate cancer (mCRPC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The open-label study, which is underway in Australia, will evaluate the orally bioavailable chimeric degrader targeting androgen receptor (AR) HP518’s pharmacokinetics, safety and anti-tumour activity in mCRPC patients.

Hinova’s targeted protein degradation drug discovery platform discovered and developed the therapy.

HP518 showed high degradation activity against wild type AR and certain AR mutants in discovery and preclinical studies.

It also demonstrated antitumour activity in xenograft mouse models.

Furthermore, HP518 is intended to overcome the drug resistance of prostate cancer due to specific AR mutations.

Hinova Pharmaceuticals president and CEO Yuanwei Chen said: “The dosing of the first patient is a significant milestone in the progress of our efforts from drug discovery to the clinical study.

“We are excited about it and dedicated to bringing new treatment options to patients worldwide, and will continue to tirelessly advance our ongoing targeted protein degradation projects.”

HP518 is highly selective for AR, a therapeutic target validated for prostate cancer treatment.

The bifunctional small molecules, chimeric degraders, can promote target proteins degradation with high potency and selectivity.

Hinova focuses on the development of new treatments for cancers and metabolic diseases through targeted protein degradation technologies.

A targeted protein degradation drug discovery platform, established by Hinova, allows rapid screening of protein degradation activity and accomplish design and optimisation of Chimeric degraders.

The company also has experience in chemical manufacturing control of chimeric degrader compounds.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena